Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01257295
Other study ID # METC-10/22
Secondary ID
Status Completed
Phase N/A
First received December 8, 2010
Last updated December 23, 2011
Start date December 2010
Est. completion date May 2011

Study information

Verified date December 2011
Source Wageningen University
Contact n/a
Is FDA regulated No
Health authority Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study type Interventional

Clinical Trial Summary

Dietary fibers likely have a role in body weight management. They may increase satiety and, as a consequence, reduce energy intake during the next meal. There are, however, many different types of dietary fiber, which have diverse physical properties and can therefore impact these outcomes differently. It is, however, unclear whether dietary fibers with different properties lead to differences in energy intake during the next meal. The objective of this study is to study the effect of pectin in 4 different physicochemical states on ad libitum energy intake and possible underlying mechanisms; i.e. gastrointestinal hormones, gastric emptying rate, feelings of satiety and the method of fiber supplementation. We hypothesize that viscous and gelling fibers will reduce ad libitum energy intake compared to low viscous and low gelling fibers.


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date May 2011
Est. primary completion date May 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria:

- Age 18-30 year

- BMI 18.5-25 kg/m2

- Healthy as judged by the participant

Exclusion Criteria:

- Females

- Weight loss or weight gain of more than 5 kg during the last 2 months

- Using an energy restricted diet during the last 2 months

- Lack of appetite for any reason

- Restrained eater: >2.89, measured by DEBQ (35).

- Smoking

- Heavy alcohol use: >5 drinks/day (36).

- Reported stomach or bowel disease

- Reported diabetes

- Reported thyroid disease or any other endocrine disorder

- Reported intolerance for pectin, bread, gluten, dairy or not liking of the research foods

- Anemia: Hb<8.0 mmol/l

- Fasting glucose levels >5.8 mmol/l

- Blood donation from 6 weeks prior to the study until the end of the study

- Experienced any problems with drawing blood in the past

- Antecubital veins not considered suitable for blood drawing by means of a catheter

- Thesis students or employees of the division of Human Nutrition

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
control: no fiber addition
liquid breakfast without addition of fiber
breakfast with low viscous, low gelling pectin
10g of low viscous, low gelling pectin dissolved in a liquid breakfast
high viscous, low gelling pectin
10g of high viscous, low gelling pectin dissolved in a liquid breakfast
low viscous, high gelling pectin
10g of low viscous, high gelling pectin dissolved in a liquid breakfast
high viscous, high gelling pectin
10g of high viscous, high gelling pectin dissolved in a liquid breakfast
pectin supplement
10g of high viscous, high gelling pectin provided as a dietary supplement, a liquid breakfast is served seperately

Locations

Country Name City State
Netherlands Wageningen University Wageningen

Sponsors (1)

Lead Sponsor Collaborator
Wageningen University

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary energy intake 3 hours after ingesting the test breakfast ad libitum energy intake is measured. 3 hours No
Secondary appetite sensations appetite is measured by VAS scales over a period of 3 hours after ingestion of a test breakfast 3 hours No
Secondary satiety hormones satiety hormones (ghrelin, PYY, GLP-1, CCK) are measured over a period of 3 hours after ingestion of a test breakfast 3 hours No
Secondary gastric emptying rate gastric emptying rate is measured over a period of 3 hours after ingestion of a test breakfast 3 hours No
Secondary method of supplementation One of the fibers will be offered as tablets that will be ingested with a glass of water right after the test meal. 3 hours No
See also
  Status Clinical Trial Phase
Completed NCT05621447 - A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects Phase 1
Completed NCT02901366 - Mass Balance Study of FYU-981 Phase 2
Not yet recruiting NCT01928563 - Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine Phase 1
Completed NCT05559554 - A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects Phase 1
Completed NCT04512872 - A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects Phase 1
Active, not recruiting NCT06111196 - Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects Phase 1
Completed NCT03317652 - Effect of Sodium Nitroprusside on Cerebral Blood Flow N/A
Completed NCT04655872 - Mass Balance of Oral [14C]TPN171H in Healthy Male Subjects Phase 1
Active, not recruiting NCT02609711 - Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects Phase 1
Withdrawn NCT02560363 - A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects Phase 1
Completed NCT01261260 - Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers Phase 1
Completed NCT05072028 - Mass Balance and Biotransformation Study of [14C]DBPR108 in Human Phase 1
Completed NCT05446233 - ADME Study of [14C] Antaitavir Hasophate in Healthy Male Subjects Phase 1
Completed NCT05275010 - A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System Phase 1
Completed NCT04839744 - A Comparative Study of TG103 Produced by Two Manufacturing Processes in Chinese Healthy Male Subjects Phase 1
Completed NCT05792917 - Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers Phase 1
Completed NCT03576651 - A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers Phase 1
Completed NCT04825431 - Mass Balance Study of [14C] TAS-205 in Healthy Volunteers Phase 1
Completed NCT01819779 - Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60) Phase 1
Completed NCT05126784 - AVT03 With Prolia in Healthy Male Subjects Phase 1